Faecal microbiota transplantation has gained increasing attention over the last decade as
various phenotypes could be transferred from a donor to a recipient in different animal
models. Clinically, however, the sole indication with evidence from a randomized placebo
controlled trial is refractory Clostridium difficile infection. Despite revealing successful
clinical outcomes, questions concerning regulatory affairs, the identification of the best
donor, the optimal mixture of the transplant as well as the preferred route of administration …